Companies with long-term, capital-intensive goals and no immediate path to profitability are being valued like biotech firms. Both public and private markets are willing to fund these "moonshots" for years before revenue materializes, a model familiar in drug development but novel for mainstream tech.
The current tech landscape is not a universally rising tide. While investor enthusiasm buoys AI-native companies, the disruptive threat of large language models is simultaneously depressing valuations and venture capital interest for traditional software companies whose business models are now at risk.
Palantir argues that enterprises going directly to LLM providers like OpenAI face high costs and vendor lock-in. Its strategy is to act as an intermediary, building custom, model-agnostic applications on client data, promising better business outcomes despite its own premium price tag.
Unlike typical IPOs where institutional investors inflate orders, demand for SpaceX is considered more genuine. This suggests major buyers are long-term holders, not "renters" looking for a quick flip, which could lead to more stable post-IPO trading and less initial volatility.
Anthropic's policy of retaining Fable model inputs for 30 days for safety monitoring is a roadblock for regulated industries (legal, medical) and enterprises like Microsoft concerned with data control. However, developers focused on coding are more willing to accept the risk for the model's superior performance.
NASDAQ's rapid inclusion of SpaceX in its QQQ index caters to investor demand for hot tech stocks. Conversely, the S&P 500's delay is a prudent move to avoid market dislocations, given the vastly larger amount of capital tied to its index. Both decisions are logical for their specific market positions.